Press Releases
LRA Announces Inaugural Awards Promoting Diversity in Lupus Research

NEW YORK, NY, June 9, 2022. The Lupus Research Alliance (LRA), the world’s leading private funder of lupus research, today announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Award funding mechanisms aim to address underrepresentation of minorities in the scientific research profession. Lupus […] READ MORE

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] READ MORE

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE

Lupus Research Alliance Grants $6 Million in First Global Team Science Awards

This Largest-Ever Grant Will Fund Two Projects Examining Why Lupus Differs for Each Person NEW YORK, NY. Sept. 21, 2021. Today, the Lupus Research Alliance is pleased to announce the inaugural recipients of its largest grant to date, the Global Team Science Award, which will fund international, multidisciplinary research teams to unravel lupus heterogeneity with […] READ MORE

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] READ MORE

Together, ManyOne Can make a difference!
Stay informed about events, research developments, and ways you can help. Sign up for updates